New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For DVA;HUM;AGN;AET;EPOC;BAYRY;COV;MDT;BMY;CI;MCK;WLP;BDX From The Last 14 Days
Check below for free stories on DVA;HUM;AGN;AET;EPOC;BAYRY;COV;MDT;BMY;CI;MCK;WLP;BDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 19, 2014
17:14 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTAGNAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
14:40 EDTAGNSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
13:13 EDTAGNAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTAGNSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTAGNAllergan approached Salix about takeover, WSJ reports
08:40 EDTMDTMedtronic sees FY15 gross margin of 74.5%-75%, with Q2 on lower end of range
Subscribe for More Information
08:25 EDTMDTMedtronic: Negative factors in Spine segment in Q1 werre temporary
Subscribe for More Information
08:22 EDTMDT, COVMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
07:19 EDTMDTMedtronic backs FY15 EPS view of $4.00-$4.10, consensus $4.04
Subscribe for More Information
07:17 EDTMDTMedtronic reports Q1 EPS 93c, consensus 92c
Reports Q1 revenue $4.27B, consensus $4.25B.
August 18, 2014
16:10 EDTCOVCovidien says study shows directional atherectomy safe, effective
Covidien announced that directional atherectomy is "safe and effective as a frontline therapy for the treatment of peripheral arterial disease," according to a Covidien study published online today in the Journal of American College of Cardiology, Cardiovascular Interventions. Results from the DEFINITIVE LE study using Covidienís TurboHawk and/or SilverHawk directional atherectomy systems demonstrated 95% limb salvage in patients with critical limb ischemia and 78% overall patency in claudicant patients at 12 months.
15:59 EDTAGNAllergan CFO change may suggest strategic deal near, says BMO Capital
BMO Capital believes former Allergan (AGN) CFO Jeff Edwards would not be leaving if a change of control of the company, such as a takeover by Valeant (VRX), were in the future. Rather, BMO thinks Edwards' decision to leave could be a sign that a strategic transaction marking a new chapter in Allergan's growth may be nearing. The firm thinks Allergan is in capable hands with new CFO Jim Hindman and it keeps an Outperform rating on the stock with a $230 price target.
15:26 EDTMDTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:49 EDTMDTMedtronic technical comments before earnings
Subscribe for More Information
13:59 EDTMDTMedtronic August weekly 63.5 straddle priced for 2% move into Q1
Subscribe for More Information
11:57 EDTAGNAllergan CFO departure largely unexpected, says Wells Fargo
Subscribe for More Information
09:02 EDTAGNAllergan names Jim Hindman as CFO, effective immediately
Subscribe for More Information
07:57 EDTBMY, AGNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
06:24 EDTMDTOptions expected to be active
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use